Fresh analysis indicates that individuals who discontinue new GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle plans.
Research printed in a leading medical journal demonstrates that while obese people can lose a large proportion of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month after stopping.
"Users purchasing such medications need to be cognizant of the risk of rapid weight regain when the therapy ends," cautioned expert Dr. Susan Jebb.
That rate of recovery implies a return to original weight in about a year and a half.
Weighing Therapies
The research, which reviewed dozens of trials involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with older methods.
Scientists emphasize that individuals who shed pounds through diet and exercise usually have a more gradual creep back—approximately 0.1 kg a month—once they finish.
The Reason for the Quick Regain
Experts suggest the way of the drugs is key to understanding the accelerated regain.
The injections mimic a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of the hormone concentrations several times higher than normal might result in the system to produce less of its endogenous hormone, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' means hunger is unsuppressed, making binge eating much more probable."
A Chronic Condition?
The NHS recommend the injections for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals argue that, due to the significant potential of weight regain, the treatment should be considered life-long.
This view is echoed by pharmaceutical companies, who state that the findings "highlight the chronic nature of excess weight," comparing it to managing diseases like diabetes.
Patient Experiences
People who have come off the medication report a intense resurgence of cravings.
"I experienced a switch flipping and you become extremely hungry," described one woman.
This challenge is compounded if patients have not adopted sustainable lifestyle or habit changes during therapy.
Growing Adoption
Recent estimates show that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with demand being substantial.
- Use is higher among women than males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
In conclusion, clinicians caution that while the jabs are potent agents for weight loss, they are not a magic fix and maintained weight loss likely depends on combined lifestyle management.
